Shin Poong Pharmaceutical Co., Ltd. Seeks US Partners for Hyaluronic Acid Portfolio
Shin Poong is currently commercializing its portfolio of HA specialty products in Asia and other international markets. Approved and addressable indications include facial aesthetics, tissue adhesion barriers, and viscosupplementation. A young and growing patent portfolio covers the HA specialty product platforms.
For additional information about Shin Poong’s portfolio of proprietary hyaluronic acid specialty product platforms, please visit www.shinpoongusa.com.
About Shin Poong Pharma
Shin Poong Pharmaceutical Company is a publicly traded company established in 1962 in Seoul, South Korea. It is one of the ten largest pharmaceutical companies in Korea with manufacturing operations in five countries, more than 1,600 employees world-wide, and sales in excess of US $240 million. The company is collaborating with the World Health Organization on the development of a novel anti-malarial drug.
For further information, please visit the website at www.shinpoong.co.kr.
Contact:
Joseph Kozikowski, MD U.S. Medical Director
(858) 350-4288
www.shinpoongusa.com